{"transactions":[{"id":1852812,"issuer":{"id":6116,"kind":"organization","name":"STANDARD BIOTOOLS INC."},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-17T00:41:59.000Z","date":"2023-06-14","kind":"grant","planned":false,"acquired":true,"shares":35380,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Option becomes exercisable in twelve equal monthly increments beginning on July 14, 2023 subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":35380,"derivative":{"exercise_price":2.18,"expiration_date":"2033-06-14","underlying":"Common Stock","underlying_shares":35380},"source":{"system":"sec-edgar","filing":"0001162194-23-000041","document":"wk-form4_1686962510.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1162194/000116219423000041/wk-form4_1686962510.xml","form_type":"4"}},{"id":1852811,"issuer":{"id":6116,"kind":"organization","name":"STANDARD BIOTOOLS INC."},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-17T00:41:59.000Z","date":"2023-06-14","kind":"grant","planned":false,"acquired":true,"shares":26376,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of Restricted Stock Units. Each Restricted Stock Unit represents the right to receive one share of common stock upon vesting. The Restricted Stock Units vest in full on the earlier to occur of June 14, 2024 and one day prior to the date of the Company's next annual meeting of stockholders subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":104791,"source":{"system":"sec-edgar","filing":"0001162194-23-000041","document":"wk-form4_1686962510.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1162194/000116219423000041/wk-form4_1686962510.xml","form_type":"4"}},{"id":2228390,"issuer":{"id":6116,"kind":"organization","name":"STANDARD BIOTOOLS INC."},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-17T22:04:26.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":42571,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Option becomes exercisable in twelve equal monthly increments beginning on July 15, 2022."}],"balance_after":42571,"derivative":{"exercise_price":1.86,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":42571},"source":{"system":"sec-edgar","filing":"0001162194-22-000075","document":"wf-form4_165550345180060.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1162194/000116219422000075/wf-form4_165550345180060.xml","form_type":"4"}},{"id":2228389,"issuer":{"id":6116,"kind":"organization","name":"STANDARD BIOTOOLS INC."},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-17T22:04:26.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":30914,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents Restricted Stock Units that vest in full on the earlier to occur of June 15, 2023 and one day prior to the date of the Issuer's next annual meeting of stockholders. The Reporting Person has deferred settlement of the Restricted Stock Units until the earlier to occur of the Reporting Person's termination of service and a change of control."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents Restricted Stock Units with respect to which the Reporting Person has deferred settlement as described above."}],"balance_after":78415,"source":{"system":"sec-edgar","filing":"0001162194-22-000075","document":"wf-form4_165550345180060.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1162194/000116219422000075/wf-form4_165550345180060.xml","form_type":"4"}},{"id":2273423,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-05-13T00:45:55.000Z","date":"2022-05-11","kind":"sale","acquired":false,"shares":1375,"price":21.51,"value":29576.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.51 to $21.52, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":35655,"source":{"system":"sec-edgar","filing":"0001209191-22-028707","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919122028707/doc4.xml","form_type":"4"}},{"id":2273422,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-05-13T00:45:55.000Z","date":"2022-05-10","kind":"sale","acquired":false,"shares":825,"price":21.51,"value":17745.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units."}],"balance_after":37030,"source":{"system":"sec-edgar","filing":"0001209191-22-028707","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919122028707/doc4.xml","form_type":"4"}},{"id":2289905,"issuer":{"id":7058,"kind":"organization","name":"Genasys Inc."},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":true}}],"security":"Stock Option","published_at":"2022-04-27T23:02:41.000Z","date":"2022-04-27","kind":"exercise","acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":1.33,"exercise_date":"2014-05-10","expiration_date":"2022-05-10","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001437749-22-009944","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/924383/000143774922009944/rdgdoc.xml","form_type":"4"}},{"id":2289904,"issuer":{"id":7058,"kind":"organization","name":"Genasys Inc."},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-04-27T23:02:41.000Z","date":"2022-04-27","kind":"exercise","acquired":true,"shares":50000,"price":1.33,"value":66500.0,"ownership":{"direct":true},"balance_after":284311,"source":{"system":"sec-edgar","filing":"0001437749-22-009944","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/924383/000143774922009944/rdgdoc.xml","form_type":"4"}},{"id":2328959,"issuer":{"id":7058,"kind":"organization","name":"Genasys Inc."},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-03-17T19:36:31.000Z","date":"2022-03-15","kind":"grant","acquired":true,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 15, 2022, the issuer granted to the reporting person 30,000 restricted stock units (RSUs) that vest on the anniversary date of the grant.  Each RSU represents a contingent right to one share of Genasys Inc. common stock and is eligible to be settled solely in shares of Genasys Inc. common stock."}],"balance_after":234311,"source":{"system":"sec-edgar","filing":"0001437749-22-006570","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/924383/000143774922006570/rdgdoc.xml","form_type":"4"}},{"id":2376042,"issuer":{"id":7058,"kind":"organization","name":"Genasys Inc."},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":true}}],"security":"Stock Option","published_at":"2022-02-24T18:54:44.000Z","date":"2022-02-23","kind":"exercise","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":2.16,"exercise_date":"2016-03-18","expiration_date":"2022-03-18","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001437749-22-004289","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/924383/000143774922004289/rdgdoc.xml","form_type":"4"}},{"id":2376041,"issuer":{"id":7058,"kind":"organization","name":"Genasys Inc."},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-02-24T18:54:44.000Z","date":"2022-02-23","kind":"sale","acquired":false,"shares":13716,"price":3.14,"value":43068.24,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions ranging from $3.10 to $3.20, inclusive.  The reporting owner undertakes to provide Genasys Inc. and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 2 of this Form 4."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"The reporting person disposed of these shares to cover the cost and tax withholding obligations related to exercising the options that were scheduled to expire March 18, 2022."}],"balance_after":204311,"source":{"system":"sec-edgar","filing":"0001437749-22-004289","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/924383/000143774922004289/rdgdoc.xml","form_type":"4"}},{"id":2376040,"issuer":{"id":7058,"kind":"organization","name":"Genasys Inc."},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-02-24T18:54:44.000Z","date":"2022-02-23","kind":"exercise","acquired":true,"shares":20000,"price":2.16,"value":43200.0,"ownership":{"direct":true},"balance_after":218027,"source":{"system":"sec-edgar","filing":"0001437749-22-004289","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/924383/000143774922004289/rdgdoc.xml","form_type":"4"}},{"id":2416355,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Performance-based restricted stock units","published_at":"2022-02-02T21:17:25.000Z","date":"2022-01-31","kind":"grant","acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each performance-based restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This grant will vest upon the achievement of specified clinical/regulatory milestones, provided, however, if the vesting events occur before the date that is 24 months after the date of grant, then the award will instead vest on the date that is 24 months after the date of grant, and provided further that the Performance RSU will expire on January 31, 2026 if the specified performance based milestones are not achieved by such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"This grant will vest upon the achievement of specified clinical/regulatory milestones, provided, however, if the vesting events occur before the date that is 24 months after the date of grant, then the award will instead vest on the date that is 24 months after the date of grant, and provided further that the Performance RSU will expire on January 31, 2026 if the specified performance based milestones are not achieved by such date."}],"balance_after":8000,"derivative":{"underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001209191-22-006362","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919122006362/doc4.xml","form_type":"4"}},{"id":2416354,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Performance-based restricted stock units","published_at":"2022-02-02T21:17:25.000Z","date":"2022-01-31","kind":"grant","acquired":true,"shares":9840,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each performance-based restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This grant will vest upon the achievement of specified clinical/regulatory and commercial milestones, provided, however, if either vesting event occurs before the date that is 12 months after the date of grant, then the portion of the award that would have vested upon such event will instead vest on the date that is 12 months after the date of grant, and provided further that the Performance RSU will expire on January 31, 2027 to the extent the specified performance based milestones are not achieved by such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"This grant will vest upon the achievement of specified clinical/regulatory and commercial milestones, provided, however, if either vesting event occurs before the date that is 12 months after the date of grant, then the portion of the award that would have vested upon such event will instead vest on the date that is 12 months after the date of grant, and provided further that the Performance RSU will expire on January 31, 2027 to the extent the specified performance based milestones are not achieved by such date."}],"balance_after":9840,"derivative":{"underlying":"Common Stock","underlying_shares":9840},"source":{"system":"sec-edgar","filing":"0001209191-22-006362","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919122006362/doc4.xml","form_type":"4"}},{"id":2416353,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee stock option (right to buy)","published_at":"2022-02-02T21:17:25.000Z","date":"2022-01-31","kind":"grant","acquired":true,"shares":39360,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter."}],"balance_after":39360,"derivative":{"exercise_price":27.5,"expiration_date":"2032-01-30","underlying":"Common Stock","underlying_shares":39360},"source":{"system":"sec-edgar","filing":"0001209191-22-006362","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919122006362/doc4.xml","form_type":"4"}},{"id":2416352,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-02-02T21:17:25.000Z","date":"2022-01-31","kind":"sale","acquired":false,"shares":1238,"price":27.4,"value":33921.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units."}],"balance_after":37855,"source":{"system":"sec-edgar","filing":"0001209191-22-006362","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919122006362/doc4.xml","form_type":"4"}},{"id":2416351,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-02-02T21:17:25.000Z","date":"2022-01-31","kind":"grant","acquired":true,"shares":9840,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan that are scheduled to vest over four years."}],"balance_after":39093,"source":{"system":"sec-edgar","filing":"0001209191-22-006362","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919122006362/doc4.xml","form_type":"4"}},{"id":2425113,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-01-26T21:34:17.000Z","date":"2022-01-24","kind":"sale","acquired":false,"shares":2063,"price":24.98,"value":51533.74,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units."}],"balance_after":29253,"source":{"system":"sec-edgar","filing":"0001209191-22-005080","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919122005080/doc4.xml","form_type":"4"}},{"id":2436757,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-01-12T21:05:27.000Z","date":"2022-01-11","kind":"sale","acquired":false,"shares":7500,"price":27.4,"value":205500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units."}],"balance_after":31316,"source":{"system":"sec-edgar","filing":"0001209191-22-003046","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919122003046/doc4.xml","form_type":"4"}},{"id":2436756,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-01-12T21:05:27.000Z","date":"2022-01-10","kind":"grant","acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 1, 2015, the reporting person was granted a performance restricted stock unit (PRSU) grant covering 15,000 shares of the Issuer's common stock, which vest upon the later of (i) 12 months from the date of grant and (ii) the achievement of specified performance milestones. On January 10, 2022, PRSUs covering 7,500 shares of the Issuer's common stock vested upon the Issuer's confirmation that the Issuer's fiscal 2021 net reported revenue exceeded $200 million."}],"balance_after":38816,"source":{"system":"sec-edgar","filing":"0001209191-22-003046","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919122003046/doc4.xml","form_type":"4"}},{"id":2599893,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-08-17T23:34:43.000Z","date":"2021-08-17","kind":"sale","acquired":false,"shares":1407,"price":17.1182,"value":24085.3074,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested performance restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a \"sell to cover\" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person."}],"balance_after":31316,"source":{"system":"sec-edgar","filing":"0001209191-21-052077","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919121052077/doc4.xml","form_type":"4"}},{"id":2599892,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-08-17T23:34:43.000Z","date":"2021-08-13","kind":"grant","acquired":true,"shares":4500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 31, 2020, the reporting person was granted a performance restricted stock unit (PRSU) grant covering 9,000 shares of the Issuer's common stock, which vest upon the later of (i) 12 months from the date of grant and (ii) the achievement of specified clinical and regulatory development milestones. On August 13, 2021, a portion of the PRSUs vested upon the Issuer's confirmation of the satisfaction of a performance criterion related to the interim data read-out from the PROTECT study."}],"balance_after":32723,"source":{"system":"sec-edgar","filing":"0001209191-21-052077","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919121052077/doc4.xml","form_type":"4"}},{"id":2693774,"issuer":{"id":6116,"kind":"organization","name":"STANDARD BIOTOOLS INC."},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-27T21:28:10.000Z","date":"2021-05-25","kind":"grant","acquired":true,"shares":15402,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Option becomes exercisable in twelve equal monthly increments beginning on June 25, 2021."}],"balance_after":15402,"derivative":{"exercise_price":5.56,"expiration_date":"2031-05-25","underlying":"Common Stock","underlying_shares":15402},"source":{"system":"sec-edgar","filing":"0001162194-21-000059","document":"wf-form4_162215080437619.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1162194/000116219421000059/wf-form4_162215080437619.xml","form_type":"4"}},{"id":2693773,"issuer":{"id":6116,"kind":"organization","name":"STANDARD BIOTOOLS INC."},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-27T21:28:10.000Z","date":"2021-05-25","kind":"grant","acquired":true,"shares":10342,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents Restricted Stock Units that vest in full on the earlier to occur of May 25, 2022 and one day prior to the date of the Company's next annual meeting of stockholders. The Reporting Person has deferred settlement of the Restricted Stock Units until the earlier to occur of the Reporting Person's termination of service and a change of control."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents Restricted Stock Units with respect to which the Reporting Person has deferred settlement as described above."}],"balance_after":47501,"source":{"system":"sec-edgar","filing":"0001162194-21-000059","document":"wf-form4_162215080437619.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1162194/000116219421000059/wf-form4_162215080437619.xml","form_type":"4"}},{"id":2714340,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-05-13T20:07:48.000Z","date":"2021-05-12","kind":"sale","acquired":false,"shares":2000,"price":19.46,"value":38920.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units."}],"balance_after":28223,"source":{"system":"sec-edgar","filing":"0001209191-21-032314","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919121032314/doc4.xml","form_type":"4"}},{"id":2714339,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-05-13T20:07:48.000Z","date":"2021-05-11","kind":"sale","acquired":false,"shares":2000,"price":19.14,"value":38280.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units."}],"balance_after":30223,"source":{"system":"sec-edgar","filing":"0001209191-21-032314","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919121032314/doc4.xml","form_type":"4"}},{"id":2780148,"issuer":{"id":7058,"kind":"organization","name":"Genasys Inc."},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-03-18T20:52:32.000Z","date":"2021-03-16","kind":"grant","acquired":true,"shares":27883,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 16, 2021, the issuer granted to the reporting person 27,883 restricted stock units (RSUs) that vest on the one year anniversary of the date of grant.  Each RSU represents a contingent right to receive one share of Genasys Inc. common stock and is eligible to be settled solely in shares of Genasys Inc. common stock."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"On March 16, 2021, the issuer granted to the reporting person 27,883 restricted stock units (RSUs) that vest on the one year anniversary of the date of grant.  Each RSU represents a contingent right to receive one share of Genasys Inc. common stock and is eligible to be settled solely in shares of Genasys Inc. common stock."}],"balance_after":168027,"source":{"system":"sec-edgar","filing":"0001437749-21-006509","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/924383/000143774921006509/rdgdoc.xml","form_type":"4"}},{"id":2793004,"issuer":{"id":7058,"kind":"organization","name":"Genasys Inc."},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":true}}],"security":"Stock Option","published_at":"2021-03-12T17:43:56.000Z","date":"2021-03-10","kind":"exercise","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":2.02,"exercise_date":"2015-03-26","expiration_date":"2021-03-26","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001437749-21-005857","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/924383/000143774921005857/rdgdoc.xml","form_type":"4"}},{"id":2793003,"issuer":{"id":7058,"kind":"organization","name":"Genasys Inc."},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-03-12T17:43:56.000Z","date":"2021-03-10","kind":"sale","acquired":false,"shares":5456,"price":7.4166,"value":40464.9696,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions ranging from $7.40 to $7.465, inclusive. The reporting owner undertakes to provide Genasys Inc. and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 2 of this Form 4."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"The reporting person disposed of these shares to cover the cost and tax withholding obligations related to exercising the options that were scheduled to expire March 26, 2021."}],"balance_after":170144,"source":{"system":"sec-edgar","filing":"0001437749-21-005857","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/924383/000143774921005857/rdgdoc.xml","form_type":"4"}},{"id":2793002,"issuer":{"id":7058,"kind":"organization","name":"Genasys Inc."},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-03-12T17:43:56.000Z","date":"2021-03-10","kind":"exercise","acquired":true,"shares":20000,"price":2.02,"value":40400.0,"ownership":{"direct":true},"balance_after":175600,"source":{"system":"sec-edgar","filing":"0001437749-21-005857","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/924383/000143774921005857/rdgdoc.xml","form_type":"4"}},{"id":2839872,"issuer":{"id":6116,"kind":"organization","name":"STANDARD BIOTOOLS INC."},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-24T02:58:39.000Z","date":"2021-02-20","kind":"grant","acquired":true,"shares":9803,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents Restricted Stock Units that vest in four equal quarterly installments beginning on March 15, 2021. The Reporting Person has deferred settlement of the Restricted Stock Units until the earlier to occur of the Reporting Person's termination of service and a change of control."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents Restricted Stock Units with respect to which the Reporting Person has deferred settlement as described above."}],"balance_after":37159,"source":{"system":"sec-edgar","filing":"0001162194-21-000009","document":"wf-form4_161413548118979.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1162194/000116219421000009/wf-form4_161413548118979.xml","form_type":"4"}},{"id":2871689,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-02-09T21:29:15.000Z","date":"2021-02-08","kind":"sale","acquired":false,"shares":2250,"price":31.58,"value":71055.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units that was reported on February 5, 2021."}],"balance_after":32223,"source":{"system":"sec-edgar","filing":"0001209191-21-008802","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919121008802/doc4.xml","form_type":"4"}},{"id":2871688,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-02-09T21:29:15.000Z","date":"2021-02-05","kind":"sale","acquired":false,"shares":2250,"price":31.41,"value":70672.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units that was reported on February 5, 2021."}],"balance_after":34473,"source":{"system":"sec-edgar","filing":"0001209191-21-008802","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919121008802/doc4.xml","form_type":"4"}},{"id":2876575,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-02-05T21:46:51.000Z","date":"2021-02-03","kind":"grant","acquired":true,"shares":4500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"(1)  On January 31, 2020, the reporting person was granted a performance restricted stock unit (PRSU) grant covering 9,000 shares of the Issuer's common stock, which vest upon the later of (i) 12 months from the date of grant and (ii) the achievement of specified clinical and regulatory development milestones. On February 3, 2021, a portion of the PRSUs vested upon the Issuer's confirmation of the satisfaction of a performance criterion related to the interim data read-out from the DUPLEX study."}],"balance_after":36723,"source":{"system":"sec-edgar","filing":"0001209191-21-008111","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919121008111/doc4.xml","form_type":"4"}},{"id":2881533,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-02-04T02:30:47.000Z","date":"2021-02-03","kind":"sale","acquired":false,"shares":1125,"price":28.91,"value":32523.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units."}],"balance_after":32223,"source":{"system":"sec-edgar","filing":"0001209191-21-007632","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919121007632/doc4.xml","form_type":"4"}},{"id":2881532,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-02-04T02:30:47.000Z","date":"2021-02-03","kind":"sale","acquired":false,"shares":2500,"price":28.91,"value":72275.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units."}],"balance_after":33348,"source":{"system":"sec-edgar","filing":"0001209191-21-007632","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919121007632/doc4.xml","form_type":"4"}},{"id":2885408,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-02-03T02:19:22.000Z","date":"2021-02-02","kind":"sale","acquired":false,"shares":1125,"price":30.75,"value":34593.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units."}],"balance_after":35848,"source":{"system":"sec-edgar","filing":"0001209191-21-007024","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919121007024/doc4.xml","form_type":"4"}},{"id":2885407,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-02-03T02:19:22.000Z","date":"2021-02-02","kind":"sale","acquired":false,"shares":2500,"price":30.75,"value":76875.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units."}],"balance_after":36973,"source":{"system":"sec-edgar","filing":"0001209191-21-007024","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919121007024/doc4.xml","form_type":"4"}},{"id":2885406,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-02-03T02:19:22.000Z","date":"2021-01-31","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 31, 2020, the reporting person was granted a performance restricted stock unit (PRSU) grant covering 10,000 shares of the Issuer's common stock, which vest upon the later of (i) 12 months from the date of grant and (ii) the achievement of specified clinical and regulatory development milestones. On January 31, 2021, a portion of the PRSUs vested upon the 12 month anniversary of the date of grant, following the Issuer's prior confirmation of the satisfaction of a performance criterion related to the full enrollment of the DUPLEX study."}],"balance_after":39473,"source":{"system":"sec-edgar","filing":"0001209191-21-007024","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919121007024/doc4.xml","form_type":"4"}},{"id":2897592,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee stock option (right to buy)","published_at":"2021-01-26T01:55:14.000Z","date":"2021-01-21","kind":"grant","acquired":true,"shares":57500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter."}],"balance_after":57500,"derivative":{"exercise_price":26.88,"expiration_date":"2031-01-20","underlying":"Common Stock","underlying_shares":57500},"source":{"system":"sec-edgar","filing":"0001209191-21-005250","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919121005250/doc4.xml","form_type":"4"}},{"id":2897591,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-01-26T01:55:14.000Z","date":"2021-01-21","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan that are scheduled to vest over four years."}],"balance_after":34473,"source":{"system":"sec-edgar","filing":"0001209191-21-005250","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919121005250/doc4.xml","form_type":"4"}},{"id":2966028,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-11-26T00:00:09.000Z","date":"2020-11-25","kind":"sale","acquired":false,"shares":3750,"price":22.72,"value":85200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units."}],"balance_after":19473,"source":{"system":"sec-edgar","filing":"0001209191-20-060591","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919120060591/doc4.xml","form_type":"4"}},{"id":2966027,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-11-26T00:00:09.000Z","date":"2020-11-24","kind":"sale","acquired":false,"shares":3750,"price":23.86,"value":89475.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units."}],"balance_after":23223,"source":{"system":"sec-edgar","filing":"0001209191-20-060591","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919120060591/doc4.xml","form_type":"4"}},{"id":2966026,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-11-26T00:00:09.000Z","date":"2020-11-23","kind":"grant","acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 17, 2017, the reporting person was granted performance restricted stock units (PRSUs) covering 15,000 shares of the Issuer's common stock, which vest upon the satisfaction of certain performance criteria. On November 23, 2020, a portion of the PRSUs vested upon the Issuer's confirmation of the satisfaction of a performance criterion."}],"balance_after":26973,"source":{"system":"sec-edgar","filing":"0001209191-20-060591","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919120060591/doc4.xml","form_type":"4"}},{"id":2977351,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-11-18T02:00:13.000Z","date":"2020-11-16","kind":"sale","acquired":false,"shares":7500,"price":23.975,"value":179812.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.68 to $24.485,\ninclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and\nExchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":19473,"source":{"system":"sec-edgar","filing":"0001209191-20-058945","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919120058945/doc4.xml","form_type":"4"}},{"id":2981043,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-11-14T02:24:43.000Z","date":"2020-11-13","kind":"sale","acquired":false,"shares":7500,"price":23.6095,"value":177071.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.36 to $24.105,\ninclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and\nExchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":26973,"source":{"system":"sec-edgar","filing":"0001209191-20-058417","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919120058417/doc4.xml","form_type":"4"}},{"id":2981042,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-11-14T02:24:43.000Z","date":"2020-11-11","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 19, 2016, the reporting person was granted performance restricted stock units (PRSUs) covering 15,000 shares of the Issuer's common stock, which vest upon the satisfaction of certain performance criteria. On November 11, 2020, the PRSUs vested upon the Issuer's confirmation that the Issuer had completed a significant acquisition."}],"balance_after":34473,"source":{"system":"sec-edgar","filing":"0001209191-20-058417","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919120058417/doc4.xml","form_type":"4"}},{"id":3023596,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-09-24T00:00:10.000Z","date":"2020-09-23","kind":"sale","acquired":false,"shares":1500,"price":18.48,"value":27720.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation\nthat occurred upon the vesting of performance restricted stock units."}],"balance_after":19473,"source":{"system":"sec-edgar","filing":"0001209191-20-051732","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919120051732/doc4.xml","form_type":"4"}},{"id":3024905,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-09-23T01:18:03.000Z","date":"2020-09-22","kind":"sale","acquired":false,"shares":1500,"price":18.59,"value":27885.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation\nthat occurred upon the vesting of performance restricted stock units."}],"balance_after":20973,"source":{"system":"sec-edgar","filing":"0001209191-20-051612","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919120051612/doc4.xml","form_type":"4"}},{"id":3024904,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-09-23T01:18:03.000Z","date":"2020-09-18","kind":"grant","acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 9, 2019, the reporting person was granted performance restricted stock units (PRSUs) covering 6,000 shares of the Issuer's common stock, which vest upon the satisfaction of certain performance criteria. On September 18, 2020, a portion of the PRSUs vested upon the Issuer's confirmation that the first 280 patients in the sparsentan PROTECT Phase 3 Study had been enrolled."}],"balance_after":22473,"source":{"system":"sec-edgar","filing":"0001209191-20-051612","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919120051612/doc4.xml","form_type":"4"}},{"id":3100056,"issuer":{"id":6116,"kind":"organization","name":"STANDARD BIOTOOLS INC."},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-25T19:59:54.000Z","date":"2020-06-23","kind":"grant","acquired":true,"shares":20993,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Option becomes exercisable in twelve equal monthly increments beginning on July 23, 2020."}],"balance_after":20993,"derivative":{"exercise_price":3.74,"expiration_date":"2030-06-23","underlying":"Common Stock","underlying_shares":20993},"source":{"system":"sec-edgar","filing":"0001162194-20-000084","document":"wf-form4_159311517662198.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1162194/000116219420000084/wf-form4_159311517662198.xml","form_type":"4"}},{"id":3100055,"issuer":{"id":6116,"kind":"organization","name":"STANDARD BIOTOOLS INC."},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-25T19:59:54.000Z","date":"2020-06-23","kind":"grant","acquired":true,"shares":13369,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents Restricted Stock Units that vest in full on the earlier to occur of June 23, 2021 and one day prior to the date of the Company's next annual meeting of stockholders. The Reporting Person has deferred settlement of the Restricted Stock Units until the earlier to occur of the Reporting Person's termination of service and a change of control."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents Restricted Stock Units with respect to which the Reporting Person has deferred settlement as described above."}],"balance_after":27356,"source":{"system":"sec-edgar","filing":"0001162194-20-000084","document":"wf-form4_159311517662198.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1162194/000116219420000084/wf-form4_159311517662198.xml","form_type":"4"}},{"id":3150795,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-05-14T01:00:12.000Z","date":"2020-05-12","kind":"sale","acquired":false,"shares":527,"price":16.9843,"value":8950.7261,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a \"sell to cover\" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person."}],"balance_after":19473,"source":{"system":"sec-edgar","filing":"0001209191-20-029022","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919120029022/doc4.xml","form_type":"4"}},{"id":3150794,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-05-14T01:00:12.000Z","date":"2020-05-12","kind":"sale","acquired":false,"shares":1250,"price":17.16,"value":21450.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units."}],"balance_after":20000,"source":{"system":"sec-edgar","filing":"0001209191-20-029022","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919120029022/doc4.xml","form_type":"4"}},{"id":3150793,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-05-14T01:00:12.000Z","date":"2020-05-11","kind":"sale","acquired":false,"shares":1250,"price":14.95,"value":18687.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units."}],"balance_after":21250,"source":{"system":"sec-edgar","filing":"0001209191-20-029022","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919120029022/doc4.xml","form_type":"4"}},{"id":3213427,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-03-12T23:43:46.000Z","date":"2020-03-10","kind":"sale","acquired":false,"shares":4000,"price":15.02,"value":60080.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.855 to $15.21,\ninclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and\nExchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":22500,"source":{"system":"sec-edgar","filing":"0001209191-20-018647","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919120018647/doc4.xml","form_type":"4"}},{"id":3214266,"issuer":{"id":7058,"kind":"organization","name":"Genasys Inc."},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":true}}],"security":"Restricted Stock units","published_at":"2020-03-12T22:49:26.000Z","date":"2020-03-12","kind":"exercise","acquired":false,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"No purchase price, conversion price or exercise price was paid because the restricted stock units converted into shares of common stock on a one-for-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"No purchase price, conversion price or exercise price was paid because the restricted stock units converted into shares of common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The reporting person received a grant of 30,000 RSU's on March 12, 2019.  These vested on March 12, 2020 and the reporting person received one share of Genasys Inc. common stock for each RSU."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The reporting person received a grant of 30,000 RSU's on March 12, 2019.  These vested on March 12, 2020 and the reporting person received one share of Genasys Inc. common stock for each RSU."}],"balance_after":0,"derivative":{"underlying":"common stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001437749-20-004995","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/924383/000143774920004995/rdgdoc.xml","form_type":"4"}},{"id":3214265,"issuer":{"id":7058,"kind":"organization","name":"Genasys Inc."},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":true}}],"security":"Common stock","published_at":"2020-03-12T22:49:26.000Z","date":"2020-03-12","kind":"exercise","acquired":true,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F2","text":"The reporting person received a grant of 30,000 RSU's on March 12, 2019.  These vested on March 12, 2020 and the reporting person received one share of Genasys Inc. common stock for each RSU."},{"field":"shares","element":"transactionShares","label":"F2","text":"The reporting person received a grant of 30,000 RSU's on March 12, 2019.  These vested on March 12, 2020 and the reporting person received one share of Genasys Inc. common stock for each RSU."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"No purchase price, conversion price or exercise price was paid because the restricted stock units converted into shares of common stock on a one-for-one basis."}],"balance_after":155600,"source":{"system":"sec-edgar","filing":"0001437749-20-004995","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/924383/000143774920004995/rdgdoc.xml","form_type":"4"}},{"id":3214264,"issuer":{"id":7058,"kind":"organization","name":"Genasys Inc."},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":true}}],"security":"Common stock","published_at":"2020-03-12T22:49:26.000Z","date":"2020-03-10","kind":"grant","acquired":true,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On March 10, 2020, the issuer granted to the reporting person 30,000 restricted stock units (RSU's) that vest on the one year anniversary of the date of grant.  Each RSU represents a contingent right to receive one share of Genasys Inc. common stock and is eligible to be settled solely in shares of Genasys Inc. common stock."},{"field":"shares","element":"transactionShares","label":"F1","text":"On March 10, 2020, the issuer granted to the reporting person 30,000 restricted stock units (RSU's) that vest on the one year anniversary of the date of grant.  Each RSU represents a contingent right to receive one share of Genasys Inc. common stock and is eligible to be settled solely in shares of Genasys Inc. common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 10, 2020, the issuer granted to the reporting person 30,000 restricted stock units (RSU's) that vest on the one year anniversary of the date of grant.  Each RSU represents a contingent right to receive one share of Genasys Inc. common stock and is eligible to be settled solely in shares of Genasys Inc. common stock."}],"balance_after":125600,"source":{"system":"sec-edgar","filing":"0001437749-20-004995","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/924383/000143774920004995/rdgdoc.xml","form_type":"4"}},{"id":3220335,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-03-10T01:06:11.000Z","date":"2020-03-05","kind":"grant","acquired":true,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 10, 2018, the reporting person was granted performance restricted stock units (PRSUs) covering 8,000 shares of the Issuer's common stock, which vest upon the satisfaction of certain performance criteria.  On March 5, 2020, a portion of the PRSUs vested upon the Issuer's confirmation that the first 190 patients in the sparsentan DUPLEX Phase 3 Study had been enrolled."}],"balance_after":26500,"source":{"system":"sec-edgar","filing":"0001209191-20-017539","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919120017539/doc4.xml","form_type":"4"}},{"id":3296571,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Performance-based restricted stock units","published_at":"2020-02-01T01:15:47.000Z","date":"2020-01-31","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This grant will vest upon the later of (i) 12 months from the date of grant and (ii) the achievement of specified clinical and regulatory development milestones, provided that the grant will expire on January 31, 2024 to the extent the specified clinical and regulatory milestones are not achieved by such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"This grant will vest upon the later of (i) 12 months from the date of grant and (ii) the achievement of specified clinical and regulatory development milestones, provided that the grant will expire on January 31, 2024 to the extent the specified clinical and regulatory milestones are not achieved by such date."}],"balance_after":10000,"derivative":{"underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-20-005900","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919120005900/doc4.xml","form_type":"4"}},{"id":3296570,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Performance-based restricted stock units","published_at":"2020-02-01T01:15:47.000Z","date":"2020-01-31","kind":"grant","acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This grant will vest upon the later of (i) 12 months from the date of grant and (ii) the achievement of specified clinical and regulatory development milestones, provided that the grant will expire on January 31, 2024 to the extent the specified clinical and regulatory milestones are not achieved by such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"This grant will vest upon the later of (i) 12 months from the date of grant and (ii) the achievement of specified clinical and regulatory development milestones, provided that the grant will expire on January 31, 2024 to the extent the specified clinical and regulatory milestones are not achieved by such date."}],"balance_after":9000,"derivative":{"underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001209191-20-005900","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919120005900/doc4.xml","form_type":"4"}},{"id":3296569,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee stock option (right to buy)","published_at":"2020-02-01T01:15:47.000Z","date":"2020-01-31","kind":"grant","acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter."}],"balance_after":55000,"derivative":{"exercise_price":15.46,"expiration_date":"2030-01-30","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001209191-20-005900","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919120005900/doc4.xml","form_type":"4"}},{"id":3296568,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-02-01T01:15:47.000Z","date":"2020-01-31","kind":"grant","acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":22500,"source":{"system":"sec-edgar","filing":"0001209191-20-005900","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919120005900/doc4.xml","form_type":"4"}},{"id":3500861,"issuer":{"id":6116,"kind":"organization","name":"STANDARD BIOTOOLS INC."},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-05T17:38:46.000Z","date":"2019-06-03","kind":"grant","acquired":true,"shares":6796,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Option becomes exercisable in twelve equal monthly installments beginning on July 3, 2019."}],"balance_after":6796,"derivative":{"exercise_price":13.41,"expiration_date":"2029-06-03","underlying":"Common Stock","underlying_shares":6796},"source":{"system":"sec-edgar","filing":"0001162194-19-000049","document":"wf-form4_155975631163949.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1162194/000116219419000049/wf-form4_155975631163949.xml","form_type":"4"}},{"id":3500860,"issuer":{"id":6116,"kind":"organization","name":"STANDARD BIOTOOLS INC."},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-05T17:38:46.000Z","date":"2019-06-03","kind":"grant","acquired":true,"shares":3987,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents Restricted Stock Units that vest in full on the earlier to occur of June 3, 2020 and one day prior to the date of the Issuer's next annual meeting of stockholders. The Reporting Person has deferred settlement of the Restricted Stock Units until the earlier to occur of the Reporting Person's termination of service and a change of control."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents Restricted Stock Units with respect to which the Reporting Person has deferred settlement as described above."}],"balance_after":13987,"source":{"system":"sec-edgar","filing":"0001162194-19-000049","document":"wf-form4_155975631163949.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1162194/000116219419000049/wf-form4_155975631163949.xml","form_type":"4"}},{"id":3523736,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-05-17T01:37:06.000Z","date":"2019-05-16","kind":"sale","acquired":false,"shares":1250,"price":18.71,"value":23387.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units."}],"balance_after":13500,"source":{"system":"sec-edgar","filing":"0001209191-19-030660","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919119030660/doc4.xml","form_type":"4"}},{"id":3523735,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-05-17T01:37:06.000Z","date":"2019-05-15","kind":"sale","acquired":false,"shares":1250,"price":17.78,"value":22225.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.64 to $17.85,\ninclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and\nExchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":14750,"source":{"system":"sec-edgar","filing":"0001209191-19-030660","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919119030660/doc4.xml","form_type":"4"}},{"id":3531470,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Performance-based restricted stock units","published_at":"2019-05-11T01:40:23.000Z","date":"2019-05-09","kind":"grant","acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This grant will vest upon the later of (i) 12 months from the date of grant, and (ii) the achievement of specified clinical and regulatory milestones, provided that the grant will expire on May 9, 2023 to the extent the specified clinical and regulatory milestones are not achieved by such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"This grant will vest upon the later of (i) 12 months from the date of grant, and (ii) the achievement of specified clinical and regulatory milestones, provided that the grant will expire on May 9, 2023 to the extent the specified clinical and regulatory milestones are not achieved by such date."}],"balance_after":6000,"derivative":{"underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001209191-19-029174","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919119029174/doc4.xml","form_type":"4"}},{"id":3531469,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee stock option (right to buy)","published_at":"2019-05-11T01:40:23.000Z","date":"2019-05-09","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter."}],"balance_after":40000,"derivative":{"exercise_price":17.96,"expiration_date":"2029-05-08","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-19-029174","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919119029174/doc4.xml","form_type":"4"}},{"id":3531468,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-05-11T01:40:23.000Z","date":"2019-05-09","kind":"grant","acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":16000,"source":{"system":"sec-edgar","filing":"0001209191-19-029174","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919119029174/doc4.xml","form_type":"4"}},{"id":3585107,"issuer":{"id":7058,"kind":"organization","name":"Genasys Inc."},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2019-03-20T23:17:56.000Z","date":"2019-03-20","kind":"exercise","acquired":false,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"No purchase price, conversion price or exercise price was paid because the restricted stock units converted into shares of common stock on a one-for-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"No purchase price, conversion price or exercise price was paid because the restricted stock units converted into shares of common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reporting person received a grant of 25,000 Restricted Stock Units (RSUs) on March 20, 2018. These vested on March 20, 2019 and the reporting person received one share of LRAD Corporation common stock for each RSU."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The reporting person received a grant of 25,000 Restricted Stock Units (RSUs) on March 20, 2018. These vested on March 20, 2019 and the reporting person received one share of LRAD Corporation common stock for each RSU."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001437749-19-005369","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/924383/000143774919005369/rdgdoc.xml","form_type":"4"}},{"id":3585106,"issuer":{"id":7058,"kind":"organization","name":"Genasys Inc."},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":true}}],"security":"Common stock","published_at":"2019-03-20T23:17:56.000Z","date":"2019-03-20","kind":"exercise","acquired":true,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person received a grant of 25,000 Restricted Stock Units (RSUs) on March 20, 2018. These vested on March 20, 2019 and the reporting person received one share of LRAD Corporation common stock for each RSU."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"No purchase price, conversion price or exercise price was paid because the restricted stock units converted into shares of common stock on a one-for-one basis."}],"balance_after":95600,"source":{"system":"sec-edgar","filing":"0001437749-19-005369","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/924383/000143774919005369/rdgdoc.xml","form_type":"4"}},{"id":3598219,"issuer":{"id":7058,"kind":"organization","name":"Genasys Inc."},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2019-03-14T01:41:14.000Z","date":"2019-03-12","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of LRAD common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"RSUs vest on March 12, 2020. Expiration date is not applicable to RSUs."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"RSUs vest on March 12, 2020. Expiration date is not applicable to RSUs."}],"balance_after":30000,"derivative":{"underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001437749-19-004853","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/924383/000143774919004853/rdgdoc.xml","form_type":"4/A","original_submission_date":"2019-03-13"}},{"id":3598344,"issuer":{"id":7058,"kind":"organization","name":"Genasys Inc."},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2019-03-14T00:48:40.000Z","date":"2020-03-12","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of LRAD common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"RSUs vest on March 12, 2020. Expiration date is not applicable to RSUs."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"RSUs vest on March 12, 2020. Expiration date is not applicable to RSUs."}],"balance_after":30000,"derivative":{"underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001437749-19-004842","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/924383/000143774919004842/rdgdoc.xml","form_type":"4"}},{"id":3660272,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-02-14T01:49:01.000Z","date":"2019-02-12","kind":"sale","acquired":false,"shares":1016,"price":21.5,"value":21844.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001209191-19-009925","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919119009925/doc4.xml","form_type":"4"}},{"id":3660271,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-02-14T01:49:01.000Z","date":"2019-02-11","kind":"sale","acquired":false,"shares":1017,"price":21.38,"value":21743.46,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units."}],"balance_after":11016,"source":{"system":"sec-edgar","filing":"0001209191-19-009925","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919119009925/doc4.xml","form_type":"4"}},{"id":3721304,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-12-22T01:19:20.000Z","date":"2018-12-21","kind":"sale","acquired":false,"shares":900,"price":22.3433,"value":20108.97,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.285 to $22.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and\nExchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":12033,"source":{"system":"sec-edgar","filing":"0001209191-18-064021","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919118064021/doc4.xml","form_type":"4"}},{"id":3721303,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-12-22T01:19:20.000Z","date":"2018-12-21","kind":"sale","acquired":false,"shares":2850,"price":21.6671,"value":61751.235,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.25 to $22.17,\ninclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and\nExchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":12933,"source":{"system":"sec-edgar","filing":"0001209191-18-064021","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919118064021/doc4.xml","form_type":"4"}},{"id":3721302,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-12-22T01:19:20.000Z","date":"2018-12-20","kind":"sale","acquired":false,"shares":3750,"price":22.0812,"value":82804.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.78 to $22.51, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":15783,"source":{"system":"sec-edgar","filing":"0001209191-18-064021","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919118064021/doc4.xml","form_type":"4"}},{"id":3723285,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-12-21T00:59:45.000Z","date":"2018-12-18","kind":"grant","acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 17, 2017, the reporting person was granted performance restricted stock units (PRSUs) covering 15,000 shares of the Issuer's common stock, which vest upon the satisfaction of certain performance criteria. On December 18, 2018, a portion of the PRSUs vested upon the Issuer's confirmation that the Phase 3 FORT study of fosmetpantotenate in PKAN had fully enrolled."}],"balance_after":19533,"source":{"system":"sec-edgar","filing":"0001209191-18-063776","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919118063776/doc4.xml","form_type":"4"}},{"id":3760832,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-11-17T00:16:50.000Z","date":"2018-11-15","kind":"sale","acquired":false,"shares":791,"price":24.7306,"value":19561.9046,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.67 to $24.805, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":12033,"source":{"system":"sec-edgar","filing":"0001209191-18-059064","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919118059064/doc4.xml","form_type":"4"}},{"id":3760831,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-11-17T00:16:50.000Z","date":"2018-11-15","kind":"sale","acquired":false,"shares":2959,"price":24.1991,"value":71605.1369,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.65 to $24.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":12824,"source":{"system":"sec-edgar","filing":"0001209191-18-059064","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919118059064/doc4.xml","form_type":"4"}},{"id":3760830,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-11-17T00:16:50.000Z","date":"2018-11-14","kind":"sale","acquired":false,"shares":400,"price":24.54,"value":9816.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.38 to $24.76, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and\nExchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":15783,"source":{"system":"sec-edgar","filing":"0001209191-18-059064","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919118059064/doc4.xml","form_type":"4"}},{"id":3760829,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-11-17T00:16:50.000Z","date":"2018-11-14","kind":"sale","acquired":false,"shares":3350,"price":23.6282,"value":79154.47,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.35 to $23.95,\ninclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and\nExchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":16183,"source":{"system":"sec-edgar","filing":"0001209191-18-059064","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919118059064/doc4.xml","form_type":"4"}},{"id":3764531,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-11-15T01:43:31.000Z","date":"2018-11-09","kind":"grant","acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 1, 2015, the reporting person was granted performance restricted stock units (PRSUs) covering 15,000 shares of the Issuer's common stock, which vest upon the satisfaction of certain performance criteria.  On November 9, 2018, a portion of the PRSUs vested upon the Issuer's confirmation that the US Food and Drug Administration had accepted for review a New Drug Application filed by the Issuer's partner."}],"balance_after":19533,"source":{"system":"sec-edgar","filing":"0001209191-18-058648","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919118058648/doc4.xml","form_type":"4"}},{"id":3778233,"issuer":{"id":6116,"kind":"organization","name":"STANDARD BIOTOOLS INC."},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-11-02T00:16:09.000Z","date":"2018-10-30","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares underlying the Option will vest each anniversary after the date of grant on the same day of the month as the date of grant, subject to continued service as a director."}],"balance_after":15000,"derivative":{"exercise_price":7.42,"expiration_date":"2028-10-30","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001162194-18-000101","document":"wf-form4_154111775356789.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1162194/000116219418000101/wf-form4_154111775356789.xml","form_type":"4"}},{"id":3778232,"issuer":{"id":6116,"kind":"organization","name":"STANDARD BIOTOOLS INC."},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-11-02T00:16:09.000Z","date":"2018-10-30","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each Restricted Stock Unit represents the contingent right to receive one share of FLDM common stock upon vesting of the unit."},{"field":"shares","element":"transactionShares","label":"F2","text":"25% of the shares underlying the Restricted Stock Units will vest each anniversary after the date of grant on the same day of the month as the date of grant, subject to continued service as a director. The Reporting Person has deferred settlement of the Restricted Stock Units to occur within the thirty (30) day period immediately following the earlier to occur of: (a) the Reporting Person's termination of service with the Issuer; or (b) a Change of Control (as defined in the Company's 2011 Equity Incentive Plan)."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001162194-18-000101","document":"wf-form4_154111775356789.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1162194/000116219418000101/wf-form4_154111775356789.xml","form_type":"4"}},{"id":3934672,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Performance-based restricted stock units","published_at":"2018-05-14T23:32:35.000Z","date":"2018-05-10","kind":"grant","acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This grant will vest upon the later of (i) 12 months from the date of grant, and (ii) the achievement of specified clinical and regulatory milestones, provided that the grant will expire on May 10, 2022 to the extent the specified clinical and regulatory milestones are not achieved by such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"This grant will vest upon the later of (i) 12 months from the date of grant, and (ii) the achievement of specified clinical and regulatory milestones, provided that the grant will expire on May 10, 2022 to the extent the specified clinical and regulatory milestones are not achieved by such date."}],"balance_after":8000,"derivative":{"underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001209191-18-030056","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919118030056/doc4.xml","form_type":"4"}},{"id":3934671,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee stock option (right to buy)","published_at":"2018-05-14T23:32:35.000Z","date":"2018-05-10","kind":"grant","acquired":true,"shares":48000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter."}],"balance_after":48000,"derivative":{"exercise_price":25.25,"expiration_date":"2028-05-09","underlying":"Common Stock","underlying_shares":48000},"source":{"system":"sec-edgar","filing":"0001209191-18-030056","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919118030056/doc4.xml","form_type":"4"}},{"id":3934670,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-05-14T23:32:35.000Z","date":"2018-05-10","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":12033,"source":{"system":"sec-edgar","filing":"0001209191-18-030056","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919118030056/doc4.xml","form_type":"4"}},{"id":3986764,"issuer":{"id":7058,"kind":"organization","name":"Genasys Inc."},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2018-03-21T18:18:49.000Z","date":"2018-03-20","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of LRAD common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"RSUs vest on March 20, 2019. Expiration date is not applicable to RSUs."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"RSUs vest on March 20, 2019. Expiration date is not applicable to RSUs."}],"balance_after":95600,"derivative":{"underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001437749-18-005139","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/924383/000143774918005139/rdgdoc.xml","form_type":"4"}},{"id":3993469,"issuer":{"id":7058,"kind":"organization","name":"Genasys Inc."},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2018-03-16T21:16:20.000Z","date":"2018-03-14","kind":"exercise","acquired":true,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"No purchase price, conversion price or exercise price was paid because the restricted stock units converted into shares of common stock on a one-for-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"No purchase price, conversion price or exercise price was paid because the restricted stock units converted into shares of common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reporting person received a grant of 25,000 Restricted Stock Units (RSUs) on March 14, 2017. These vested on March 14, 2018 and the reporting person received one share of LRAD Corporation common stock for each RSU."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The reporting person received a grant of 25,000 Restricted Stock Units (RSUs) on March 14, 2017. These vested on March 14, 2018 and the reporting person received one share of LRAD Corporation common stock for each RSU."}],"balance_after":70600,"derivative":{"underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001437749-18-004896","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/924383/000143774918004896/rdgdoc.xml","form_type":"4"}},{"id":3993468,"issuer":{"id":7058,"kind":"organization","name":"Genasys Inc."},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":true}}],"security":"Common stock","published_at":"2018-03-16T21:16:20.000Z","date":"2018-03-14","kind":"exercise","acquired":true,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reporting person received a grant of 25,000 Restricted Stock Units (RSUs) on March 14, 2017. These vested on March 14, 2018 and the reporting person received one share of LRAD Corporation common stock for each RSU."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"No purchase price, conversion price or exercise price was paid because the restricted stock units converted into shares of common stock on a one-for-one basis."}],"balance_after":70600,"source":{"system":"sec-edgar","filing":"0001437749-18-004896","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/924383/000143774918004896/rdgdoc.xml","form_type":"4"}},{"id":4066050,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-02-13T01:39:40.000Z","date":"2018-02-08","kind":"grant","acquired":true,"shares":2033,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":2033,"source":{"system":"sec-edgar","filing":"0001209191-18-009399","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919118009399/doc4.xml","form_type":"4"}},{"id":4312445,"issuer":{"id":7058,"kind":"organization","name":"Genasys Inc."},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2017-05-19T15:58:26.000Z","date":"2017-05-17","kind":"exercise","acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"No purchase price, conversion price or exercise price was paid because the restricted stock units converted into shares of common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"As reported on a Form 4 filed on March 16, 2017, the reporting person received a grant of 25,000 Restricted Stock Units (\"RSUs\") on March 14, 2017 which were to vest on May 17, 2017. On the vesting date, for each RSU vesting on such date, the reporting person will receive one share of LRAD Corporation common stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"As reported on a Form 4 filed on March 16, 2017, the reporting person received a grant of 25,000 Restricted Stock Units (\"RSUs\") on March 14, 2017 which were to vest on May 17, 2017. On the vesting date, for each RSU vesting on such date, the reporting person will receive one share of LRAD Corporation common stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001437749-17-009631","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/924383/000143774917009631/rdgdoc.xml","form_type":"4"}},{"id":4312444,"issuer":{"id":7058,"kind":"organization","name":"Genasys Inc."},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":true}}],"security":"Common Stock","published_at":"2017-05-19T15:58:26.000Z","date":"2017-05-17","kind":"exercise","acquired":true,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"As reported on a Form 4 filed on March 16, 2017, the reporting person received a grant of 25,000 Restricted Stock Units (\"RSUs\") on March 14, 2017 which were to vest on May 17, 2017. On the vesting date, for each RSU vesting on such date, the reporting person will receive one share of LRAD Corporation common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"No purchase price, conversion price or exercise price was paid because the restricted stock units converted into shares of common stock on a one-for-one basis."}],"balance_after":47600,"source":{"system":"sec-edgar","filing":"0001437749-17-009631","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/924383/000143774917009631/rdgdoc.xml","form_type":"4"}},{"id":4313490,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee stock option (right to buy)","published_at":"2017-05-18T22:16:05.000Z","date":"2017-05-17","kind":"grant","acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable in sixteen equal quarterly installments from the date of grant."}],"balance_after":60000,"derivative":{"exercise_price":17.44,"expiration_date":"2027-05-16","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001209191-17-033719","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919117033719/doc4.xml","form_type":"4"}},{"id":4383047,"issuer":{"id":7058,"kind":"organization","name":"Genasys Inc."},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2017-03-16T18:29:58.000Z","date":"2017-03-14","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of LRAD common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"RSUs will vest on March 14, 2018. Expiration date is not applicable to RSUs."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"RSUs will vest on March 14, 2018. Expiration date is not applicable to RSUs."}],"balance_after":25000,"derivative":{"underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001437749-17-004685","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/924383/000143774917004685/rdgdoc.xml","form_type":"4"}},{"id":4383046,"issuer":{"id":7058,"kind":"organization","name":"Genasys Inc."},"owners":[{"id":112233,"kind":"person","name":"Clague Laura","position":1,"cik":"0001388773","reported_name":"Clague Laura","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2017-03-16T18:29:58.000Z","date":"2017-03-14","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of LRAD common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"RSUs will vest on May 17, 2017. Expiration date is not applicable to RSUs."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"RSUs will vest on May 17, 2017. Expiration date is not applicable to RSUs."}],"balance_after":25000,"derivative":{"underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001437749-17-004685","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/924383/000143774917004685/rdgdoc.xml","form_type":"4"}}]}